



Curriculum Vitae Europass

Surname/ Name **Fiore Marco, MD**



Address Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milan - Italy
Telephone +39 02 2390 2910
Fax +39 02 2390 2404
E-mail marco.fiore@istitutotumori.mi.it

Citizenship Italian

Date of Birth 29th July 1975

Gender Male

Personal Experience

Date Since January 2018
Position Institutional appointment for Retroperitoneal Sarcoma Surgery
Institution **Fondazione Istituto Nazionale Tumori IRCCS**, via G. Venezian 1, 20133 **Milano**
Department of Surgery –Sarcoma Service

Date Since February 2007
Position Attending Surgeon
Institution **Fondazione Istituto Nazionale Tumori IRCCS**, via G. Venezian 1, 20133 **Milano**
Department of Surgery –Sarcoma Service

Date May 2004 – Nov 2006
Position Fellow
Institution **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Department of Surgery – Melanoma and Sarcoma Unit

Date 2003
Position Fellow
Institution **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Department of Surgery – Hepatobiliopancreatic Surgery and Liver Transplantation

Date 2002

Position Fellow
Institution **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Department of Surgery – Melanoma and Sarcoma Unit

Education

Date 2017
EORTC course 'Clinical Trial Statistics for Non Statisticians'
Institution EORTC, Brussels
International Level European Accreditation Council for Continuing Medical Education (EACCME), 21 ECMEC

Date 2001-2006
General Surgery Postgraduate Training School
Institution University of Milan
Degree 8th November 2006
International Level ISCED 5A (Field of Education: 72)

Date 1994- 2000
Medical Degree
Institution University of Milano-Bicocca
International Level ISCED 5A (Field of Education: 72)

Honors and Awards

2017 Award of the National Scientific Qualification (“Abilitazione Scientifica Nazionale”) as Associate Professor
[category 06/C1 General Surgery, expiring April 2023]
2016 International Career Development Award by SSO and ESSO
2009 International Award for the Youth - "City of Milan" Award Oncologic Research
2007 Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori Young Investigator's Award Oncologic Research
2007 Società Lombarda di Chirurgia Award Best Post-degree Thesis in General Surgery
2005 LILT Award Oncologic Research
2004 Terry Fox Price Award Oncologic Research

Memberships

- Connective Tissue Oncology Society (**CTOS**)
- Italian Sarcoma Group (**ISG**)
- European Society of Surgical Oncology (**ESSO**)
- Society of Surgical Oncology (**SSO**)
- Italian Society of Surgical Oncology (**SICO**)
- European Society of Medical Oncology (**ESMO**)
- European Organisation for Research and Treatment of Cancer (**EORTC**)

Since September 2016 Dr. Marco Fiore serves as Director of the *European School of Soft Tissue Sarcoma Surgery* (ESSO-CTOS affiliated initiative, <http://www.essoweb.org/european-school-of-sts/>)

Chair of the *Sarcoma Oncoteam* of SICO (2016-present)

Treasurer of *Surgical Oncology Division* of UEMS European Board of Surgery (2019-present)

Member of *International Committee* of the Society of Surgical Oncology (2017-2020)

Member of *Education and Training Committee* of the European Society of Surgical Oncology (2018-2020)

Member of *RESAR Governance Committee* of Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) (2018-2020)

Language

Mothertongue: **Italian**

| | Other | Comprehension | | | | Oral | | | |
|----------------|-------|---------------|----|----------|----|-------------------|----|------------------|--|
| | | Ascolto | | Lettura | | Interazione orale | | Produzione orale | |
| English | C1 | Advanced | C1 | Advanced | C1 | Advanced | C1 | Advanced | |

Milan, May 15, 2020



Marco Fiore
Sarcoma Service
Via Venezian, 1
20133 Milan - Italy
Tel. +39 02 2390 2910
Fax +39 02 2390 2404
Email: marco.fiore@istitutotumori.mi.it

English Publications

1. *Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J.* Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
2. *Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M.* Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
3. *Gronchi A, Diment J, Colecchia M, Fiore M and Santinami M.* Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
4. *Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J.* Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
5. *Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J.* Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
6. *Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG and Gronchi A.* Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005; 103:402-408.
7. *Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and Gronchi A.* Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol.* 2005; 23:7669-75.
8. *Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and Gronchi A.* Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol.* 2006; 13(1):110-7.
9. *Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and Gronchi A.* Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer.* 2006; 107(5):1065-1074.
10. *Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG.* Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245(3): 341-346.
11. *Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and Gronchi A.* Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-559
12. *Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and Gronchi A.* Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
13. *Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, and Pilotti S.* c-Kit/PDGFR Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007;13(8): 2369-2377
14. *Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG.* Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5): 1583-1590
15. *Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M and Gronchi A.* Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-3551
16. *Casanova M, Meazza C, Gronchi A, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A.* Soft-tissue sarcomas of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1:195-203
17. *Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG, Gronchi A.* Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007; 109(12): 2522-2531
18. *Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and Gronchi A.* The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. *Cancer,* 2008; 113:1657-1665
19. *Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG.* Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol,* 2008; 27:24-30
20. *Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S.* Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumours? *Translational Oncology,* 2008; Vol 1(4):177-186

21. **Fiore M**, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *EJSO*, 2009; 35: 739-745
22. *Mussi C, Ronnellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Gronchi A, Hohenberger P*. Post-Imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? *Annals of Oncology, Ann Oncol*. 2010 Feb;21(2):403-8
23. *Pennacchioli E, Fiore M, Gronchi A*. Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. *Expert Rev Anticancer Ther*, 2009; 9(2): 199-210
24. *Casanova M, Meazza C, Favini F, Fiore M, Morosi C, Ferrari A*. Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot. *Ped Hemat Oncol*, 2009; 26(5):321-331
25. *Meazza C, Bisogno G, Gronchi A, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A*. Aggressive fibromatosis in children and adolescents: the italian experience, *Cancer* 2010;116:233-240
26. *Ferrari A, Miceli R, Casanova M, Meazza C, Favini F, Luksch R, Catania S, Fiore M, Morosi C, Mariani L*. The symptom interval in children and adolescents with soft tissue sarcomas, *Cancer*, 2010; 116(1):177-183
27. **Fiore M**, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, Gronchi A and Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol*, 2009; 16(9):2587-2593
28. *Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and Gronchi A*. Subtype Specific Post-operative Nomogram for Patients affected by Primary Retroperitoneal Soft Tissue Sarcoma. *Cancer*, 2010; 116(10):2429-2436
29. *Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaïene H, Le Péchoux C, Casali PG, Le Cesne A, Fiore M and Alessandro Gronchi*. Aggressive surgery in Retroperitoneal Soft Tissue Sarcoma is safe if carried out at highvolume centers and is associated to an improved local control. *Ann Surg Oncol*, 2010; 17(6):1507-1514
30. *Gronchi A; Lo Vullo S; Colombo C, Collini P, Stacchiotti S, Mariani L; Fiore M, Casali PG*. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. *Ann Surg*, 2010; 251:512-517
31. *Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A*. Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. *Ann Surg Oncol*, 2011 Mar;18(3):720-5.
32. *Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M*. Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy? *Ann Surg Oncol*, 2010; 17(12):3220-3228
33. *Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG, Gronchi A*. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010 Dec; 17(12):3229-33
34. *Gronchi A, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG*. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. *Ann Oncol*, 2011 Jul;22(7):1675-81.
35. *Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M, Gronchi A*. Morbidity of left pancreatectomy when associated with multivisceral resection for abdominal mesenchymal neoplasms. *JOP*, 2011;12(2):138-144
36. *Gronchi A, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, Casali PG*. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. *Ann Oncol*. 2012 Apr;23(4):1067-73. Epub 2011 Jul 16.
37. **Fiore M**, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, Casali PG, Gronchi A. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012 Feb; 19(2):511-8. Epub 2011 Jul 27.
38. *Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG, Gronchi A*. Leiomyosarcoma and sarcoma with myogenic differentiation: Two different entities or 2 faces of the same disease? *Cancer*. 2012 Nov 1;118(21):5349-57
39. *Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P, Gronchi A*. Technical consideration in surgery for Retroperitoneal Sarcomas: position paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. *Ann Surg Oncol*. 2012 Sep;19(9):2981-91
40. *Radaelli S, Desai A, Colombo C, Fiore M and Gronchi A*. Peri-operative Therapies for Localized Retroperitoneal Soft Tissue Sarcoma. *Oncology & Hematology Review*, 2012;8(1):65-70
41. *Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG*. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol*. 2012 Oct 30. [Epub ahead of print]
42. *Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, Gronchi A & Fiore M*. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol*. 2013 Aug;24(8):2181-9.

43. Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen B, Kerst JM, **Fiore M**, Bylina E, Hoiczyc M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JHW, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol*. 2013 Sep;20(9):2937-43.
44. Duranti L, Gronchi A, Stacchiotti S, **Fiore M**, Casali PG, Collini P, Pelosi G, Galeone G, Pastorino U. Localised thoracic sarcomas: Outcome improvement over time at a single institution. *Eur J Cancer*. 2013 Aug;49(12):2689-97.
45. Bonvalot S, Ternès N, **Fiore M**, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A, Gronchi A. Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. *Ann Surg Oncol*. 2013 Dec;20(13):4096-102
46. **Fiore M**, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-Type Fibromatosis and Pregnancy. A Multi-institutional Analysis of Recurrence and Obstetric Risk. *Ann Surg*, 2014; 259(5):973-8
47. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, **Fiore M**, Bruzzi P, Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. *Eur J Cancer*. 2014 Mar;50(4):784-92
48. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel P, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, **Fiore M**, Bonvalot S & on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. *Annals of Oncology*, 2014 Mar;25(3):578-83
49. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, **Fiore M**, Nyckowski P, Hoiczyc M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol*. 2014 Apr;40(4):412-9.
50. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, **Fiore M**, Gronchi A, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L, Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer*. 2014 Sep 23;111(7):1350-62
51. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, **Fiore M**, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijder S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). *Ann Oncol*. 2015 May;26(5):865-872.
52. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Pechoux C, **Fiore M**, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Sylvie Bonvalot. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. *Ann Surg Oncol*. 2015 May;22(5):1447-54
53. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, Gronchi A, **Fiore M**. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiary reference sarcoma center. *Eur J Surg Oncol* 40 (2014), 1662-1670
54. **Fiore M**. Distinguishing Between Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcomas in the Preoperative Setting: A Work in Progress in the Era of Precision Medicine. *Ann Surg Oncol*. 2015 Apr;22(4):1055-6
55. ESMO/European Sarcoma Network Working Group. Casali PG, Blay JY, Bertuzzi A, Bielack S, Bjerkehagen B, Bonvalot S, Boukovinas I, Bruzzi P, Dei Tos AP, Dileo P, Eriksson M, Fedenko A, Ferrari A, Ferrari S, Gelderblom H, Grimer R, Gronchi A, Haas R, Hall KS, Hohenberger P, Issels R, Joensuu H, Judson I, Le Cesne A, Litière S, Martin-Broto J, Merimsky O, Montemurro M, Morosi C, Picci P, Ray-Coquard I, Reichardt P, Rutkowski P, Schlemmer M, Stacchiotti S, Torri V, Trama A, Van Coevorden F, Van der Graaf W, Vanel D, Wardelmann E, Colombo C, **Fiore M**, Mariani L, Miceli R, Pollock RE, Raut CP, Strauss D, Swallow CJ. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014 Sep;25 Suppl 3:iii102-12.
56. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, Mir O, Casali PG, Dômont J, **Fiore M**, Le Cesne A, Gronchi A and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer*, 2015 Jan;51(2):186-92
57. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, **Fiore M**, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol*. 2015 Mar;39(3):383-93.
58. Callegaro D, **Fiore M** and Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas. *Expert Rev Anticancer Ther*, 2015 May;15(5):553-67.

59. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, Gronchi A, **Fiore M**. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *British Journal of Surgery*, 2015; 102(9): 1079-87
60. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, **Fiore M**, Casali PG, Pollock RE, Raut C. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. *Ann Surg*, 2016; 263(5):1002-9
61. **Fiore M**, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, Gronchi A. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. *Eur J Cancer*, 2015(51): 2800-2807
62. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, M, Indio V, Maestro R, Gronchi A, **Fiore M**, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). *Clin Cancer Res*, 2016; 22(4): 837-46
63. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, **Fiore M**, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG, and Gronchi A. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncology*, 2016; 17(5): 671-80.
64. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, **Fiore M**, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honore C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, Gronchi A. External validation of a multi-institutional retroperitoneal sarcoma nomogram. *Cancer*. 2016 May 1;122(9):1417-24.
65. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, **Fiore M**, Gronchi A, Raspagliesi F. Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. *J Minim Invasive Gynecol*. 2016 May-Jun;23(4):647-9
66. Radaelli S, **Fiore M**, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG, Gronchi A. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surgical Oncology* 2016; 25: 125-131
67. **Fiore M**, MacNeill A, Gronchi A, Colombo C. Desmoid-Type Fibromatosis Evolving Treatment Standards. *Surg Oncol Clin N Am* 2016; 25: 803–826
68. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, **Fiore M**, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *The Journal of Investigative Dermatology* 2017 Feb;137(2):484-493.
69. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group. *Ann Surg Oncol* 2016; 23:3531-3540
70. **Fiore M**, Raut CP, Gronchi A. Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors? *Ann Surg Oncol*. 2016 Nov 29. [Epub ahead of print]
71. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, **Fiore M**, Casali PG, Pollock RE, Raut CP, Gronchi A, and Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group (TARPSWG). *Cancer* (2017); 123(11):1971-1978
72. Smith H, Tzanis D, Messiou C, Benson C, van den Hage J, **Fiore M**, Bonvalot S, Hayes AJ. The management of soft tissue tumours of the abdominal wall. *European Journal of Surgical Oncology, European J Surg Oncol*, 2017; 43(9): 1647-1655
73. Delhorme J-B, Fontana A, Levy A, Terrier P, **Fiore M**, Tzanis D, Callegaro D, Dratwa C, Gronchi A, Bonvalot S. Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. *European J Surg Oncol*, 2016 Dec 5 [Epub ahead of print]
74. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, **Fiore M**, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, Gronchi A. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in large series of patients affected by desmoid-type fibromatosis. *The Cancer Journal (United States)*, 23(2):86-91
75. MacNeill AJ, Gronchi A, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, **Fiore M**, Casali PG, Pollock RE, Barretta F, Raut CP, and Strauss DC. Post-operative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group (TARPSWG). *Annals of Surgery*, 2018; 267(5):959-964
76. Colia V, **Fiore M**, Provenzano M, Fumagalli M, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali PG and Sanfilippo R. Activity of anthracycline and ifosfamide based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res* (2017) 7:16

77. Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, **Fiore M**, Stacchiotti S, Palassini E, Gronchi A, Pilotti S, Perrone F. β -Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. *Mol Oncol*. 2017 Jun 19. doi: 10.1002/1878-0261.12101. [Epub ahead of print]
78. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, **Fiore M**, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. *Oncotarget*. 2017 May 17;8(36):60036-60045
79. MacNeill A, **Fiore M**. Surgical morbidity in retroperitoneal sarcoma resection. *J Surg Oncol*. 2018 Jan;117(1):56-61
80. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, **Fiore M**, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, Gronchi A. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. *Ann Surg Oncol*. 2017; 24(13):3872-3879
81. **Fiore M**, Radaelli S, Gronchi A. Retroperitoneal Sarcoma Involving the Vena Cava. In D Azoulay, C Lim, C Salloum (eds.), *Surgery of the Inferior Vena Cava*, Springer International Publishing Switzerland 2017
82. Provenzano S, Raimondi A, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, **Fiore M**, Greco FG and Casali PG. Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor. *Clin Sarcoma Res* (2017) 7:20
83. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol*. 2018 Apr 1;29(4):857-871
84. **Fiore M**, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, Casali PG, Gronchi A. Adequate local control in high risk soft tissue sarcoma of the extremity treated with surgery alone at a reference centre: should radiotherapy still be a standard? *Ann Surg Oncol*. 2018 Feb 22. doi: 10.1245/s10434-018-6393-x. [Epub ahead of print]
85. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A, *Desmoid Working Group*. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol*. 2017 Oct 1;28(10):2399-2408
86. Jung E, **Fiore M**, Gronchi A, Grignol V, Pollock RE, Chong SS, Chopra S, Hamilton AS, and Tseng WW. Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. *Anticancer Res*. 2018 Jun;38(6):3535-3542
87. Schrage Y, Hartgrink H, Smith M, **Fiore M**, Rutkowski P, Tzanis D, Messiou C, Servois V, Bonvalot S, van der Hage J. Surgical management of metastatic gastrointestinal stromal tumour. *Eur J Surg Oncol* 2018, 44(9): 1295-1300
88. Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, Paielli N, Perrone F, Tarantino G, Palassini E, **Fiore M**, Pession A, Stacchiotti S, Pantaleo MA, Gronchi A. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. *Genes Chromosomes Cancer*. 2018;57:495–503
89. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, **Fiore M**, Dei Tos AP, Smith HG, Catton C, Casali PG, Wunder JS, Gronchi A. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centers. *Eur J Cancer*. 2018 Dec;105:19-27.
90. Ferraris M, Callegaro D, Barretta F, **Fiore M**, Radaelli S, Stacchiotti S, Miceli R, Socrate AM, Locati P, Gronchi A. Outcome of iliocaaval resection and reconstruction for retroperitoneal sarcoma. *J Vasc Surg Venous Lymphat Disord*. 2019 Jul;7(4):547-556
91. Almond M, Tirota F, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford S, Gronchi A, **Fiore M**, Morosi C. Diagnostic Accuracy of Percutaneous Biopsy in Retroperitoneal Sarcoma. *Br J Surg*. 2019 Mar;106(4):395-403
92. **Fiore M**, Gronchi A. ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. *Annals of Surgical Oncology*, 2018 Dec;25(Suppl 3):942-943.
93. Nizri E, **Fiore M**, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, Casali PG, Gronchi A. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis. *J Surg Oncol* 2019;119:318-323
94. Haas RLM, Bonvalot S, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Gladdy R, Jakob J, Szacht M, **Fiore M**, Chung PW, van Houdt WJ, Raut CP, Gronchi A. Radiotherapy for Retroperitoneal Liposarcoma: A Report From the Transatlantic Retroperitoneal Sarcoma Working Group. *Cancer*. 2019 Apr 15;125(8):1290-1300
95. Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, **Fiore M**, Fairweather M, Gronchi A. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. *Clin Cancer Res*. 2019 Apr 15;25(8):2664-2671

96. *Giannini L, Incandela F, Fiore M, Gronchi A, Stacchiotti S, Sangalli C, Piazza C.* Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. *Front Oncol.* 2018 Oct 17;8:449.
97. *Tirotta F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, Casali PG, Gronchi A, Fiore M.* Management of complicated tumor response to tyrosine kinase inhibitors in gastrointestinal stromal tumors (GIST). *J Surg Oncol* 2019;120:256-261
98. *Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, Collini P, Sangalli C, Gandola L, Diletto B, Morosi C, Fiore M, Massimino M, Ferrari A.* Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single center series. *Med Oncol.* 2019 May 18;36(7):59
99. *Dingley B, Fiore M, Gronchi A.* Personalizing surgical margins in retroperitoneal sarcomas: an update. *Exp Rev Anticancer Therapy,* 2019 Jul;19(7):613-631
100. *Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Stacchiotti S, Casali PG, Miceli R and Gronchi A.* Intraperitoneal invasion of retroperitoneal sarcomas- a risk factor for dismal prognosis. *Ann Surg Oncol,* 2019;26(11):3535-3541
101. *Transatlantic Australasian Retroperitoneal Sarcoma Working Group.* Intercontinental collaborative experience with abdominal, retroperitoneal and pelvic schwannomas. *British Journal of Surgery,* 2019, <https://doi.org/10.1002/bjs.11376>
102. *Previtali P, Fiore M, Colombo J, Arendar I, Fumagalli L, Pizzocri M, Colombo C, Rampello NN, Mariani L, Gronchi A, Codazzi D.* Malnutrition and perioperative nutritional support in retroperitoneal sarcoma patients. Results from a prospective feasibility study. *Ann Surg Oncol.* 2019;10.1245/s10434-019-08121-0. doi:10.1245/s10434-019-08121-0 [published online ahead of print, 2019 Dec 17].
103. *Gronchi A, Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VV, Levy A, Griffin A, Hayes AJ, Stacchiotti S, LePechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MA, Casali PG, Wunder JS.* Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma patients treated with surgery. *Eclinical Medicine, in press*
104. *The Desmoid Tumor Working Group.* The management of desmoid tumors: a joint global consensus-based guideline approach for adult and pediatric patients. *European Journal of Cancer,* 2020; 127:96-107
105. *IJzerman NS, Mohammadi M, Tzanis D, Gelderblom H, Fiore M, Fumagalli E, Rutkowski P, Bylina E, Zavrakidis I, Steeghs N, Bonenkamp H, van Etten B, Grünhagen DJ, Rasheed S, Tekkis P, Honoré C, van Houdt W, van der Hage J, Bonvalot S, Schrage Y, Smith M.* Quality of treatment and surgical approach for rectal Gastrointestinal Stromal Tumour (GIST) in a large European cohort. *European Journal of Surgical Oncology, in press*
106. *Tirotta F, Morosi C, Hodson J, Desai A, Barisella M, Ford SJ, Gronchi A, Almond LM and Fiore M.* Improved biopsy accuracy in retroperitoneal dedifferentiated liposarcoma. *Annals of Surgical Oncology, epub ahead of print* <https://doi.org/10.1245/s10434-020-08519-1>
107. *COVIDSurg Collaborative.* Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *The Lancet, in press*
108. *COVIDSurg Collaborative.* Elective surgery cancellations due to the SARS-Cov-2 pandemic: predictive modelling in 190 countries to inform post-pandemic surgical recovery plans. *British Journal of Surgery, submitted*
109. *Tirotta F, and Fiore M.* ASO Author Reflections: Advances in Retroperitoneal Liposarcoma Management May Benefit from Improved Biopsy Accuracy. *Ann Surg Oncol, epub ahead of prints* <https://doi.org/10.1245/s10434-020-08543-1>

H-index: 43 (Source Scopus, updated April 2020)

H-index: 45 (Source Google Scholar, updated April 2020)

i10-index: 70 (Source Google Scholar, updated April 2020)